{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T20:39:38Z","timestamp":1782160778976,"version":"3.54.5"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T00:00:00Z","timestamp":1734652800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T00:00:00Z","timestamp":1734652800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s40256-024-00712-x","type":"journal-article","created":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T18:44:50Z","timestamp":1734720290000},"page":"293-306","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Inclisiran as a siRNA Inhibitor of Proprotein Convertase Subtilisin\/Kexin Type 9 (PCSK9); Past, Present, and Future"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0447-7186","authenticated-orcid":false,"given":"Taha","family":"Mansoor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bassam Hamid","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kartik","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachin S.","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dmitry","family":"Abramov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anurag","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Al Rifai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salim S.","family":"Virani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijay","family":"Nambi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul Mannan Khan","family":"Minhas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santhosh K. G.","family":"Koshy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,20]]},"reference":[{"key":"712_CR1","doi-asserted-by":"crossref","unstructured":"Reiter-Brennan C, Osei AD, Uddin SMI, Orimoloye OA, Obisesan OH, Mirbolouk M, et al. ACC\/AHA lipid guidelines: Personalized care to prevent cardiovascular disease. Cleve Clin J Med. 2020;87:231\u20139. https:\/\/pubmed.ncbi.nlm.nih.gov\/32238379\/","DOI":"10.3949\/ccjm.87a.19078"},{"key":"712_CR2","unstructured":"De Backer G, Jankowski P, Kotseva K, Mirrakhimov E, Reiner \u017d, Ryd\u00e9n L, et al. Management of dyslipidaemia in patients with coronary heart disease: results from the ESC-EORP EUROASPIRE V survey in 27 countries. Atherosclerosis. 2019;285:135\u201346. https:\/\/pubmed.ncbi.nlm.nih.gov\/31054483\/"},{"key":"712_CR3","unstructured":"ASCVD Patients Face Barriers Reaching Guideline-Recommended Cholesterol Goals - American College of Cardiology.  https:\/\/www.acc.org\/latest-in-cardiology\/articles\/2019\/11\/09\/08\/42\/nov11-5am-ascvd-patients-face-barriers-aha-2019"},{"key":"712_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpc.2022.100336","volume":"10","author":"J Gu","year":"2022","unstructured":"Gu J, Sanchez R, Chauhan A, Fazio S, Wong N. Lipid treatment status and goal attainment among patients with atherosclerotic cardiovascular disease in the United States: a 2019 update. Am J Prev Cardiol. 2022;10: 100336.","journal-title":"Am J Prev Cardiol."},{"key":"712_CR5","doi-asserted-by":"crossref","unstructured":"Karakasis P, Patoulias D, Barkas F, Theofilis P, Milionis H, Doumas M, et al. Long-term cardiovascular safety of inclisiran: a pooled analysis of phase 3 randomized trials. Hellenic J Cardiol. 2024; https:\/\/pubmed.ncbi.nlm.nih.gov\/38908750\/","DOI":"10.1016\/j.hjc.2024.06.005"},{"key":"712_CR6","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.atherosclerosis.2020.12.013","volume":"319","author":"D Atar","year":"2021","unstructured":"Atar D, Jukema JW, Molemans B, Taub PR, Goto S, Mach F, et al. New cardiovascular prevention guidelines: How to optimally manage dyslipidaemia and cardiovascular risk in 2021 in patients needing secondary prevention? Atherosclerosis. 2021;319:51\u201361.","journal-title":"Atherosclerosis"},{"key":"712_CR7","doi-asserted-by":"crossref","unstructured":"Fowler A, Van Rompay KKA, Sampson M, Leo J, Watanabe JK, Usachenko JL, et al. A virus-like particle-based bivalent PCSK9 vaccine lowers LDL-cholesterol levels in non-human primates. npj Vaccines 2023 8:1. 2023;8:1\u201311. https:\/\/www.nature.com\/articles\/s41541-023-00743-6","DOI":"10.1038\/s41541-023-00743-6"},{"key":"712_CR8","doi-asserted-by":"crossref","unstructured":"Seidah NG, Benjannet S, Wickham L, Marcinkiewicz J, B\u00e9langer Jasmin S, Stifani S, et al. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc Natl Acad Sci U S A. 2003;100:928\u201333. https:\/\/pubmed.ncbi.nlm.nih.gov\/12552133\/","DOI":"10.1073\/pnas.0335507100"},{"key":"712_CR9","doi-asserted-by":"crossref","unstructured":"Leren TP. Mutations in the PCSK9 gene in Norwegian subjects with autosomal dominant hypercholesterolemia. Clin Genet. 2004;65:419\u201322. https:\/\/pubmed.ncbi.nlm.nih.gov\/15099351\/","DOI":"10.1111\/j.0009-9163.2004.0238.x"},{"key":"712_CR10","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","volume":"382","author":"KK Ray","year":"2020","unstructured":"Ray KK, Wright RS, Kallend D, Koenig W, Leiter LA, Raal FJ, et al. Two Phase 3 trials of Inclisiran in patients with elevated LDL cholesterol. New Engl J Med. 2020;382:1507\u201319. https:\/\/doi.org\/10.1056\/NEJMoa1912387.","journal-title":"New Engl J Med."},{"key":"712_CR11","unstructured":"FDA approves add-on therapy to lower cholesterol among certain high-risk adults | FDA. https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-add-therapy-lower-cholesterol-among-certain-high-risk-adults"},{"key":"712_CR12","unstructured":"US FDA approves expanded indication for Novartis Leqvio\u00ae (inclisiran) to include treatment of adults with high LDL-C and who are at increased risk of heart disease | Novartis United States of America. https:\/\/www.novartis.com\/us-en\/news\/media-releases\/us-fda-approves-expanded-indication-novartis-leqvio-inclisiran-include-treatment-adults-high-ldl-c-and-who-are-increased-risk-heart-disease"},{"key":"712_CR13","doi-asserted-by":"crossref","unstructured":"Scicchitano P, Milo M, Mallamaci R, De Palo M, Caldarola P, Massari F, et al. Inclisiran in lipid management: a literature overview and future perspectives. Biomed Pharmacother. 2021;143. https:\/\/pubmed.ncbi.nlm.nih.gov\/34563953\/","DOI":"10.1016\/j.biopha.2021.112227"},{"key":"712_CR14","doi-asserted-by":"crossref","unstructured":"Agrawal N, Dasaradhi PVN, Mohmmed A, Malhotra P, Bhatnagar RK, Mukherjee SK. RNA interference: biology, mechanism, and applications. Microbiol Mol Biol Rev. 2003;67:657. \/pmc\/articles\/PMC309050\/","DOI":"10.1128\/MMBR.67.4.657-685.2003"},{"key":"712_CR15","doi-asserted-by":"crossref","unstructured":"Dana H, Mahmoodi Chalbatani G, Mahmoodzadeh H, Karimloo R, Rezaiean O, Moradzadeh A, et al. Molecular mechanisms and biological functions of siRNA. Int J Biomed Sci. 2017;13:48. \/pmc\/articles\/PMC5542916\/","DOI":"10.59566\/IJBS.2017.13048"},{"key":"712_CR16","doi-asserted-by":"crossref","unstructured":"Pratt AJ, MacRae IJ. The RNA-induced silencing complex: a versatile gene-silencing machine. J Biol Chem. 2009;284:17897. \/pmc\/articles\/PMC2709356\/","DOI":"10.1074\/jbc.R900012200"},{"key":"712_CR17","doi-asserted-by":"crossref","unstructured":"Fitzgerald K, White S, Borodovsky A, Bettencourt BR, Strahs A, Clausen V, et al. A highly durable RNAi therapeutic inhibitor of PCSK9. N Engl J Med. 2017;376:41\u201351. https:\/\/pubmed.ncbi.nlm.nih.gov\/27959715\/","DOI":"10.1056\/NEJMoa1609243"},{"key":"712_CR18","doi-asserted-by":"crossref","unstructured":"Ray KK, Landmesser U, Leiter LA, Kallend D, Dufour R, Karakas M, et al. Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol. N Engl J Med. 2017;376:1430\u201340. https:\/\/pubmed.ncbi.nlm.nih.gov\/28306389\/","DOI":"10.1056\/NEJMoa1615758"},{"key":"712_CR19","doi-asserted-by":"crossref","unstructured":"Ray KK, Troquay RPT, Visseren FLJ, Leiter LA, Scott Wright R, Vikarunnessa S, et al. Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial. Lancet Diabetes Endocrinol. 2023;11:109\u201319. https:\/\/pubmed.ncbi.nlm.nih.gov\/36620965\/","DOI":"10.1016\/S2213-8587(22)00353-9"},{"key":"712_CR20","doi-asserted-by":"crossref","unstructured":"Ray KK, Stoekenbroek RM, Kallend D, Nishikido T, Leiter LA, Landmesser U, et al. Effect of 1 or 2 doses of inclisiran on low-density lipoprotein cholesterol levels: one-year follow-up of the ORION-1 randomized clinical trial. JAMA Cardiol. 2019;4:1067\u201375. https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2751334","DOI":"10.1001\/jamacardio.2019.3502"},{"key":"712_CR21","doi-asserted-by":"crossref","unstructured":"Raal FJ, Kallend D, Ray KK, Turner T, Koenig W, Wright RS, et al. Inclisiran for the treatment of heterozygous familial hypercholesterolemia. N Engl J Med. 2020;382:1520\u201330. https:\/\/pubmed.ncbi.nlm.nih.gov\/32197277\/","DOI":"10.1056\/NEJMoa1913805"},{"key":"712_CR22","doi-asserted-by":"crossref","unstructured":"Wright RS, Ray KK, Raal FJ, Kallend DG, Jaros M, Koenig W, et al. Pooled patient-level analysis of inclisiran trials in patients with familial hypercholesterolemia or atherosclerosis. J Am Coll Cardiol. 2021;77:1182\u201393. https:\/\/pubmed.ncbi.nlm.nih.gov\/33663735\/","DOI":"10.1016\/j.jacc.2020.12.058"},{"key":"712_CR23","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvae109","author":"RS Wright","year":"2024","unstructured":"Wright RS, Raal FJ, Koenig W, Landmesser U, Leiter LA, Vikarunnessa S, et al. Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trial. Cardiovasc Res. 2024. https:\/\/doi.org\/10.1093\/cvr\/cvae109.","journal-title":"Cardiovasc Res"},{"key":"712_CR24","doi-asserted-by":"crossref","unstructured":"Raal F, Durst R, Bi R, Talloczy Z, Maheux P, Lesogor A, et al. Efficacy, safety, and tolerability of inclisiran in patients with homozygous familial hypercholesterolemia: results from the ORION-5 randomized clinical trial. Circulation. 2023; https:\/\/pubmed.ncbi.nlm.nih.gov\/37850379\/","DOI":"10.1161\/CIRCULATIONAHA.122.063460"},{"key":"712_CR25","doi-asserted-by":"crossref","unstructured":"Raal FJ, Hovingh GK, Blom D, Santos RD, Harada-Shiba M, Bruckert E, et al. Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study. Lancet Diabetes Endocrinol. 2017;5:280\u201390. https:\/\/pubmed.ncbi.nlm.nih.gov\/28215937\/","DOI":"10.1016\/S2213-8587(17)30044-X"},{"key":"712_CR26","doi-asserted-by":"crossref","unstructured":"Stein EA, Honarpour N, Wasserman SM, Xu F, Scott R, Raal FJ. Effect of the proprotein convertase subtilisin\/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia. Circulation. 2013;128:2113\u201320. https:\/\/pubmed.ncbi.nlm.nih.gov\/24014831\/","DOI":"10.1161\/CIRCULATIONAHA.113.004678"},{"key":"712_CR27","doi-asserted-by":"crossref","unstructured":"Yamashita S, Kiyosue A, Maheux P, Mena-Madrazo J, Lesogor A, Shao Q, et al. Efficacy, safety, and pharmacokinetics of inclisiran in Japanese patients: results from ORION-15. J Atheroscler Thromb. 2024;31:876\u2013903. https:\/\/pubmed.ncbi.nlm.nih.gov\/38220186\/","DOI":"10.5551\/jat.64454"},{"key":"712_CR28","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1016\/j.jacc.2024.03.382","volume":"83","author":"MJ Koren","year":"2024","unstructured":"Koren MJ, Rodriguez F, East C, Toth PP, Watwe V, Abbas CA, et al. An \u201cInclisiran First\u201d strategy vs usual care in patients with atherosclerotic cardiovascular disease. J Am Coll Cardiol. 2024;83:1939\u201352.","journal-title":"J Am Coll Cardiol"},{"key":"712_CR29","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. New Engl J Med. 2017;376:1713\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1615664.","journal-title":"New Engl J Med."},{"key":"712_CR30","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","volume":"379","author":"GG Schwartz","year":"2018","unstructured":"Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. New Engl J Med. 2018;379:2097\u2013107. https:\/\/doi.org\/10.1056\/NEJMoa1801174.","journal-title":"New Engl J Med."},{"key":"712_CR31","doi-asserted-by":"crossref","unstructured":"Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372:2387\u201397. https:\/\/pubmed.ncbi.nlm.nih.gov\/26039521\/","DOI":"10.1056\/NEJMoa1410489"},{"key":"712_CR32","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","volume":"388","author":"SE Nissen","year":"2023","unstructured":"Nissen SE, Lincoff AM, Brennan D, Ray KK, Mason D, Kastelein JJP, et al. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. New Engl J Med. 2023;388:1353\u201364. https:\/\/doi.org\/10.1056\/NEJMoa2215024.","journal-title":"New Engl J Med."},{"key":"712_CR33","doi-asserted-by":"crossref","unstructured":"Lloyd-Jones DM, Morris PB, Ballantyne CM, Birtcher KK, Covington AM, DePalma SM, et al. ACC expert consensus decision pathway on the role of nonstatin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2022;80:1366\u2013418. http:\/\/www.acc.org\/Latest-in-Cardiology\/ten-points-to-remember\/2022\/08\/25\/13\/13\/2022-ACC-ECDP-on-Nonstatin","DOI":"10.1016\/j.jacc.2022.07.006"},{"key":"712_CR34","doi-asserted-by":"crossref","unstructured":"Schiele F, Quignot N, Khachatryan A, Gusto G, Villa G, Kahangire D, et al. Clinical impact and room for improvement of intensity and adherence to lipid lowering therapy: five years of clinical follow-up from 164,565 post-myocardial infarction patients. Int J Cardiol. 2021;332:22\u20138. https:\/\/pubmed.ncbi.nlm.nih.gov\/33705845\/","DOI":"10.1016\/j.ijcard.2021.03.007"},{"key":"712_CR35","doi-asserted-by":"crossref","unstructured":"Khunti K, Danese MD, Kutikova L, Catterick D, Sorio-Vilela F, Gleeson M, et al. Association of a combined measure of adherence and treatment intensity with cardiovascular outcomes in patients with atherosclerosis or other cardiovascular risk factors treated with statins and\/or ezetimibe. JAMA Netw Open. 2018;1:e185554. https:\/\/pubmed.ncbi.nlm.nih.gov\/30646277\/","DOI":"10.1001\/jamanetworkopen.2018.5554"},{"key":"712_CR36","doi-asserted-by":"crossref","unstructured":"Kasichayanula S, Grover A, Emery MG, Gibbs MA, Somaratne R, Wasserman SM, et al. Clinical pharmacokinetics and pharmacodynamics of evolocumab, a PCSK9 inhibitor. Clin Pharmacokinet. 2018;57:769. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC5999140\/","DOI":"10.1007\/s40262-017-0620-7"},{"key":"712_CR37","doi-asserted-by":"crossref","unstructured":"Luo Z, Huang Z, Sun F, Guo F, Wang Y, Kao S, et al. The clinical effects of inclisiran, a first-in-class LDL-C lowering siRNA therapy, on the LDL-C levels in Chinese patients with hypercholesterolemia. J Clin Lipidol. 2023;17:392\u2013400. http:\/\/www.lipidjournal.com\/article\/S1933287423000764\/fulltext","DOI":"10.1016\/j.jacl.2023.04.010"},{"key":"712_CR38","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1093\/eurjpc\/zwab229","volume":"29","author":"L D\u2019Erasmo","year":"2022","unstructured":"D\u2019Erasmo L, Steward K, Cefal\u00f9 AB, Di Costanzo A, Boersma E, Bini S, et al. Efficacy and safety of lomitapide in homozygous familial hypercholesterolaemia: the pan-European retrospective observational study. Eur J Prev Cardiol. 2022;29:832\u201341. https:\/\/doi.org\/10.1093\/eurjpc\/zwab229.","journal-title":"Eur J Prev Cardiol"},{"key":"712_CR39","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa2004215","volume":"383","author":"FJ Raal","year":"2020","unstructured":"Raal FJ, Rosenson RS, Reeskamp LF, Hovingh GK, Kastelein JJP, Rubba P, et al. Evinacumab for Homozygous Familial Hypercholesterolemia. New Engl J Med. 2020;383:711\u201320. https:\/\/doi.org\/10.1056\/NEJMoa2004215.","journal-title":"New Engl J Med."},{"key":"712_CR40","unstructured":"Pricey Inclisiran Is Rolling Out: a \u2018Buy-and-Bill\u2019 Model May Smooth Its Path | tctmd.com. https:\/\/www.tctmd.com\/news\/pricey-inclisiran-rolling-out-buy-and-bill-model-may-smooth-its-path"},{"key":"712_CR41","doi-asserted-by":"crossref","unstructured":"Desai NR, Campbell C, Electricwala B, Petrou M, Trueman D, Woodcock F, et al. Cost effectiveness of inclisiran in atherosclerotic cardiovascular patients with elevated low-density lipoprotein cholesterol despite statin use: a threshold analysis. Am J Cardiovasc Drugs. 2022;22. https:\/\/pubmed.ncbi.nlm.nih.gov\/35595929\/","DOI":"10.1007\/s40256-022-00534-9"},{"key":"712_CR42","doi-asserted-by":"crossref","unstructured":"Katzmann JL, Cupido AJ, Laufs U. Gene therapy targeting PCSK9. Metabolites. 2022;12:12. \/pmc\/articles\/PMC8781734\/","DOI":"10.3390\/metabo12010070"},{"key":"712_CR43","doi-asserted-by":"crossref","unstructured":"Abifadel M, Varret M, Rab\u00e8s JP, Allard D, Ouguerram K, Devillers M, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003;34:154\u20136. https:\/\/pubmed.ncbi.nlm.nih.gov\/12730697\/","DOI":"10.1038\/ng1161"},{"key":"712_CR44","doi-asserted-by":"publisher","first-page":"e17","DOI":"10.1093\/eurheartj\/ehz430","volume":"43","author":"P Guedeney","year":"2022","unstructured":"Guedeney P, Giustino G, Sorrentino S, Claessen BE, Camaj A, Kalkman DN, et al. Efficacy and safety of alirocumab and evolocumab: a systematic review and meta-analysis of randomized controlled trials. Eur Heart J. 2022;43:e17\u201325. https:\/\/doi.org\/10.1093\/eurheartj\/ehz430.","journal-title":"Eur Heart J"},{"key":"712_CR45","doi-asserted-by":"crossref","unstructured":"Preiss D, Mafham M. PCSK9 inhibition: the dawn of a new age in cholesterol lowering? Diabetologia. 2017;60:381. \/pmc\/articles\/PMC6518084\/","DOI":"10.1007\/s00125-016-4178-y"},{"key":"712_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(14)61372-3","volume":"63","author":"EA Stein","year":"2014","unstructured":"Stein EA, Kasichayanula S, Turner T, Kranz T, Arumugam U, Biernat L, et al. LDL cholesterol reduction with BMS-962476, an adnectin inhibitor of PCSK9: results of a single ascending dose study. J Am Coll Cardiol. 2014;63: A1372. https:\/\/doi.org\/10.1016\/S0735-1097(14)61372-3.","journal-title":"J Am Coll Cardiol"},{"key":"712_CR47","doi-asserted-by":"crossref","unstructured":"Klug EQ, Llerena S, Burgess LJ, Fourie N, Scott R, Vest J, et al. Efficacy and safety of lerodalcibep in patients with or at high risk of cardiovascular disease: a randomized clinical trial. JAMA Cardiol. 2024;9:800\u2013807. https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2820248","DOI":"10.1001\/jamacardio.2024.1659"},{"key":"712_CR48","doi-asserted-by":"crossref","unstructured":"Kulkarni JA, Witzigmann D, Thomson SB, Chen S, Leavitt BR, Cullis PR, et al. The current landscape of nucleic acid therapeutics. Nat Nanotechnol. 2021;16:630\u201343. https:\/\/www.nature.com\/articles\/s41565-021-00898-0","DOI":"10.1038\/s41565-021-00898-0"},{"key":"712_CR49","doi-asserted-by":"publisher","unstructured":"Gouni-Berthold I, Schwarz J, Berthold HK. Nonstatin drugs (L. Tokgozoglu and A.L. Catapano, section editors) PCSK9 monoclonal antibodies: new developments and their relevance in a nucleic acid-based therapy era. https:\/\/doi.org\/10.1007\/s11883-022-01053-3.","DOI":"10.1007\/s11883-022-01053-3"},{"key":"712_CR50","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1016\/S0735-1097(22)02466-4","volume":"79","author":"MJ Koren","year":"2022","unstructured":"Koren MJ, Hofherr A, Schumi J, Rekic D, Knochel J, Nilsson CAM, et al. Etesian: a phase 2B study of the efficacy, safety and tolerability of AZD8233, a PCSK9-targeted antisense oligonucleotide, in patients with dyslipidemia. J Am Coll Cardiol. 2022;79:1475. https:\/\/doi.org\/10.1016\/S0735-1097(22)02466-4.","journal-title":"J Am Coll Cardiol"},{"key":"712_CR51","doi-asserted-by":"crossref","unstructured":"Kosmas CE, Papakonstantinou EJ, Carre\u00f1o J, Uceta RE, Guzman E, Sourlas A. PCSK9 targeting in the management of Hypercholesterolaemia. EMJ Cardiol Cardiol. 2023;11:87\u201397. https:\/\/www.emjreviews.com\/cardiology\/article\/pcsk9-targeting-in-the-management-of-hypercholesterolaemia\/","DOI":"10.33590\/emjcardiol\/10303462"},{"key":"712_CR52","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1161\/ATVBAHA.122.317963","volume":"43","author":"RF Oostveen","year":"2023","unstructured":"Oostveen RF, Khera AV, Kathiresan S, Stroes ESG, Fitzgerald K, Harms MJ, et al. New approaches for targeting PCSK9: small-interfering ribonucleic acid and genome editing. Arterioscler Thromb Vasc Biol. 2023;43:1081\u201392. https:\/\/doi.org\/10.1161\/ATVBAHA.122.317963.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"712_CR53","doi-asserted-by":"crossref","unstructured":"Ding Q, Strong A, Patel KM, Ng SL, Gosis BS, Regan SN, et al. Permanent alteration of PCSK9 with in vivo CRISPR-Cas9 genome editing. Circ Res. 2014;115:488\u201392. https:\/\/pubmed.ncbi.nlm.nih.gov\/24916110\/.","DOI":"10.1161\/CIRCRESAHA.115.304351"},{"key":"712_CR54","doi-asserted-by":"crossref","unstructured":"Wang X, Raghavan A, Chen T, Qiao L, Zhang Y, Ding Q, et al. CRISPR-Cas9 targeting of PCSK9 in human hepatocytes in vivo-brief report. Arterioscler Thromb Vasc Biol. 2016;36:783\u20136. https:\/\/pubmed.ncbi.nlm.nih.gov\/26941020\/.","DOI":"10.1161\/ATVBAHA.116.307227"},{"key":"712_CR55","doi-asserted-by":"crossref","unstructured":"Musunuru K, Chadwick AC, Mizoguchi T, Garcia SP, DeNizio JE, Reiss CW, et al. In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates. Nature. 2021;593:429\u201334. https:\/\/www.nature.com\/articles\/s41586-021-03534-y.","DOI":"10.1038\/s41586-021-03534-y"},{"key":"712_CR56","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1080\/13543784.2024.2369747","volume":"33","author":"AJ Hooper","year":"2024","unstructured":"Hooper AJ, Tang XL, Burnett JR. VERVE-101, a CRISPR base-editing therapy designed to permanently inactivate hepatic PCSK9 and reduce LDL-cholesterol. Expert Opin Investig Drugs. 2024;33:753\u20136. https:\/\/doi.org\/10.1080\/13543784.2024.2369747.","journal-title":"Expert Opin Investig Drugs"},{"key":"712_CR57","unstructured":"VERVE-101: CRISPR-based gene editing therapy shows promise in reducing LDL-C and PCSK9 levels in patients with HeFH - American College of Cardiology. https:\/\/www.acc.org\/Latest-in-Cardiology\/Articles\/2023\/11\/08\/20\/14\/sun-445pm-heart1-aha-2023"},{"key":"712_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.jlr.2024.100524","volume":"65","author":"B Chackerian","year":"2024","unstructured":"Chackerian B, Remaley AT. PCSK9 vaccines: a promising new strategy for the treatment of hypercholesterolemia? J Lipid Res. 2024;65: 100524. https:\/\/doi.org\/10.1016\/j.jlr.2024.100524.","journal-title":"J Lipid Res"},{"key":"712_CR59","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1007\/s00228-021-03149-2","volume":"77","author":"M Zeitlinger","year":"2021","unstructured":"Zeitlinger M, Bauer M, Reindl-Schwaighofer R, Stoekenbroek RM, Lambert G, Berger-Sieczkowski E, et al. A phase I study assessing the safety, tolerability, immunogenicity, and low-density lipoprotein cholesterol-lowering activity of immunotherapeutics targeting PCSK9. Eur J Clin Pharmacol. 2021;77:1473\u201384. https:\/\/doi.org\/10.1007\/s00228-021-03149-2.","journal-title":"Eur J Clin Pharmacol"},{"key":"712_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.jlr.2024.100497","volume":"65","author":"MM Vroom","year":"2024","unstructured":"Vroom MM, Lu H, Lewis M, Thibodeaux BA, Brooks JK, Longo MS, et al. VXX-401, a novel anti-PCSK9 vaccine, reduces LDL-C in cynomolgus monkeys. J Lipid Res. 2024;65: 100497.","journal-title":"J Lipid Res"},{"key":"712_CR61","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1016\/j.jacc.2023.02.018","volume":"81","author":"CM Ballantyne","year":"2023","unstructured":"Ballantyne CM, Banka P, Mendez G, Garcia R, Rosenstock J, Rodgers A, et al. Phase 2b randomized trial of the oral PCSK9 inhibitor MK-0616. J Am Coll Cardiol. 2023;81:1553\u201364.","journal-title":"J Am Coll Cardiol"},{"key":"712_CR62","doi-asserted-by":"crossref","unstructured":"Mer\u0107ep I, Fri\u0161\u010di\u0107 N, Striki\u0107 D, Reiner \u017d. Advantages and disadvantages of inclisiran: a small interfering ribonucleic acid molecule targeting PCSK9-a narrative review. Cardiovasc Ther. 2022;2022. https:\/\/pubmed.ncbi.nlm.nih.gov\/35237348\/","DOI":"10.1155\/2022\/8129513"}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-024-00712-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40256-024-00712-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-024-00712-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T12:14:51Z","timestamp":1745324091000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40256-024-00712-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,20]]},"references-count":62,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["712"],"URL":"https:\/\/doi.org\/10.1007\/s40256-024-00712-x","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,20]]},"assertion":[{"value":"5 December 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No funding was used in the preparation of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"T.M., B.H.R., K.G., S.S.P., D.A., A.M., M.A.R., S.S.V., V.N., A.M.K.M., and S.K.G.K. declare that they have no potential conflicts of interest that might be relevant to the contents of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"T.M. carried out study conceptualization, data curation, investigation, methodology, project administration, supervision, visualization, writing, and reviewing and editing; B.H.R. K.G., S.S.P., D.A., A.M., M.A.R., S.S.V., V.N., and A.M.M.K. carried out reviewing and editing; S.K.G.K. carried out reviewing and editing, visualization, supervision, and conceptualization.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}},{"value":"Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability Statement"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}]}}